LCG
MDGL icon

Lisanti Capital Growth’s Madrigal Pharmaceuticals MDGL Stock Holding History

Lisanti Capital Growth’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,725
Closed -$4.27M – 133
2022
Q4 		$4.27M Buy
+14,725
New +$1.44M 0.58% 69

Other funds holding MDGL

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Lisanti Capital Growth's MDGL Position: Q1 2023 in Review

Lisanti Capital Growth sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2023, closing a stake of 14,725 shares — an estimated $4.27M sold.

Lisanti Capital Growth first reported a position in MDGL in Q4 2022 and held it in 1 quarter. The position peaked at $4.27M in Q4 2022. 223 funds tracked by Wall St. Rank hold MDGL as of Q1 2023.

  • Lisanti Capital Growth reported no remaining Madrigal Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Lisanti Capital Growth sold 14,725 Madrigal Pharmaceuticals shares in Q1 2023, an estimated $4.27M.
  • Lisanti Capital Growth first reported a position in Madrigal Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Lisanti Capital Growth's Madrigal Pharmaceuticals position peaked at $4.27M in Q4 2022.
  • 223 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2023.

Based on Lisanti Capital Growth's 13F filing for Q1 2023, filed 8 May 2023.